Pancreatic Cancer Research

ResearcherUniversity of FreiburgActive in the last 2 years

Heiko Becker

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6919-4048; OpenAlex author ID A5016975904, A5123862649. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
31
Papers, trials and grants by year

2017: 2 papers · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 7

  1. First-in-human EphA2-targeting PET imaging with the bicyclic radiotracer [68Ga]Ga-BCY18469 in pancreatic cancer patients: biodistribution, dosimetry and initia… Co-author DOI 10.1007/s00259-026-07985-1↗
  2. Improvement of Gemcitabine Treatment of Pancreatic Cancer by the Addition of All- trans Retinoic Acid and Identification of Vitamin A and Pentraxin 3 as Potent… Last author DOI 10.64898/2026.08.16.26359923↗
  3. Response to PD-1 inhibition in MMRd/MSS pancreatic ductal adenocarcinoma: the relevance of parallel testing. Last author DOI 10.1007/s00432-025-06334-3↗
  4. Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO … Co-author DOI 10.1007/s00432-024-05954-5↗
  5. Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and Treatment. Last author DOI 10.3390/cancers14235926↗
  6. Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations. Co-author DOI 10.1038/s41598-017-04601-z↗
  7. Author Correction: Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations. Co-author DOI 10.1038/s41598-017-14870-3↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Quante · 4 shared papers, 2022–2026 · strength 0.95
  2. Melanie Boerries · 2 shared papers, 2025–2026 · strength 0.47
  3. Dietrich Alexander Ruess · 2 shared papers, 2022–2026 · strength 0.42
  4. Ann-Christin Eder · 1 shared paper, 2026 · strength 0.27
  5. Martin Thomas Freitag · 1 shared paper, 2026 · strength 0.27
  6. Heike Luise Pahl · 1 shared paper, 2025 · strength 0.26
  7. Sarah Niessen · 1 shared paper, 2026 · strength 0.22
  8. Sophia Chikhladze · 1 shared paper, 2026 · strength 0.22
  9. Carola Focke · 1 shared paper, 2026 · strength 0.22
  10. Asmaa Elrakaybi · 1 shared paper, 2022 · strength 0.20
  11. Janna-Lisa Velthaus · 1 shared paper, 2024 · strength 0.15
  12. Sabrina Sulzer · 1 shared paper, 2024 · strength 0.15
  13. Stefanie Hegenberg · 1 shared paper, 2024 · strength 0.15
  14. Céline Lugnier · 1 shared paper, 2024 · strength 0.15
  15. Annika Kurreck · 1 shared paper, 2024 · strength 0.15
  16. Maximilian Reichert · 1 shared paper, 2024 · strength 0.15
  17. Timm M. Reißig · 1 shared paper, 2024 · strength 0.15
  18. Sebastian Lange · 1 shared paper, 2024 · strength 0.15
  19. Arndt Vogel · 1 shared paper, 2024 · strength 0.15
  20. Klara Dorman · 1 shared paper, 2024 · strength 0.15
  21. David P. Witte · 1 shared paper, 2024 · strength 0.15
  22. Georg Beyer · 1 shared paper, 2024 · strength 0.15
  23. Anke Reinacher‐Schick · 1 shared paper, 2024 · strength 0.15
  24. Christoph Benedikt Westphalen · 1 shared paper, 2024 · strength 0.15
  25. Verena Martini · 2 shared papers, 2017 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.